Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05572684 · ClinicalTrials.gov registry record · Phase 1

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors

A Phase 1 study of Ovarian Cancer and Endometrial Cancer, sponsored by NextCure.

Active
Registry status
Phase 1
Development phase
97
Enrollment target
17
Study locations

NCT05572684 is a Phase 1 study of Ovarian Cancer and Endometrial Cancer that is active but no longer recruiting, run by NextCure. The registered enrollment target is 97 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (87% lower). The trial reports 17 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05572684, a Phase 1 study of Ovarian Cancer and Endometrial Cancer, is active but no longer recruiting, sponsored by NextCure.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
97 participants
Enrollment target
17
Study locations

Study Summary

This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab. This study will also assess the clinical benefit of combination therapy in participants with advanced unresectable and/or metastatic ICI refractory solid tumors OR ICI naïve MSS/MSI-low solid tumors

Conditions Studied

Ovarian Cancer Endometrial Cancer Gastric Cancer Esophageal Cancer Advanced or Metastatic Solid Tumors Colo-rectal Cancer Head Neck Cancer Microsatellite Instability High Microsatellite Stable Microsatellite Instability Low

Interventions

  • DRUG pembrolizumab
  • DRUG NC410

Study Locations (17)

Texas

  • UT Southwestern Medical Center - Dallas
  • Texas Oncology - Baylor Charles A. Sammons Cancer Center - Dallas
  • MD Anderson Cancer Center - Houston
  • UT Health San Antonio - San Antonio
  • Texas Oncology - San Antonio - San Antonio

New York

  • Roswell Park Comprehensive Cancer Center - Buffalo
  • NYU Langone Health - New York

Virginia

  • Inova Schar Cancer Institute - Fairfax
  • Virginia Cancer Specialist - Fairfax

Arizona

  • Arizona Oncology Associates - Tucson

Colorado

  • Rocky Mountain Cancer Centers - Aurora

Kentucky

  • St. Elizabeth Edgewood Hospital - Edgewood

Louisiana

  • Ochsner Cancer Institute - New Orleans

Maryland

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Baltimore

Trial Details

FieldValue
Enrollment Target 97 participants
Start Date 2022-10-06
Est. Completion 2025-11
Phase Phase 1

Sponsor

NextCure

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05572684

The ClinicalTrials.gov registry entry for NCT05572684 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (87% lower). The listed sponsor is NextCure, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which pembrolizumab is the first listed.

NCT05572684 reports 17 study locations spanning 11 distinct geographic areas - top geographies include Texas, New York, Virginia.

Frequently Asked Questions

What is clinical trial NCT05572684 about?

NCT05572684 is a clinical study titled "A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors". This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab. This study will also assess the clinical benefit of combination therapy in participants with advanced unresectable and/or metastatic ICI refr...

What is the current status of trial NCT05572684?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 97 participants. The study started on 2022-10-06. Estimated completion is 2025-11.

What conditions does trial NCT05572684 study?

This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Gastric Cancer, Esophageal Cancer, Advanced or Metastatic Solid Tumors.

What interventions are being tested in trial NCT05572684?

The interventions under investigation include: pembrolizumab (DRUG), NC410 (DRUG).

Who is sponsoring clinical trial NCT05572684?

This trial is sponsored by NextCure, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05572684 being conducted?

This trial has 17 study locations across Arizona, Colorado, Kentucky, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ovarian Cancer

All registered trials for this condition

Endometrial Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.